Boardroom Alpha
Boardroom Alpha
OSRH · Current Report (Form 8-K) · Filed June 11, 2026

Osr Health Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 11, 2026
Period
Jun 5, 2026
Ticker
OSRH
Accession
0001213900-26-067732
Boardroom Alpha · Filing insights

OSR Holdings postpones its 2026 Annual Meeting; a new date has not yet been set.

About Osr Health Inc
Market cap
$4M
1Y TSR
−40.8%
3Y TSR
−66.6%
Board grade
D
Sector
Healthcare
CEO
Kuk Hyoun Hwang
Last annual meeting: Aug 7, 2026 · View full Osr Health Inc profile →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 5, 2026

 

OSR HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-41390   84-5052822
(State or Other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

10900 NE 4th Street, Suite 2300, Bellevue, WA   98004
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code (425) 635-7700

 

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Common stock, par value $0.0001 per share   OSRH   The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share   OSRHW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 8.01. Other Events.

  

On June 5, 2026, the Board of Directors of OSR Holdings, Inc. (the “Company”) determined to postpone the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), which had previously been scheduled to be held on June 18, 2026.

 

The Company determined that additional time is necessary to evaluate certain matters relating to the Annual Meeting and the business to be presented to stockholders. Accordingly, the Company believes that postponement of the Annual Meeting is in the best interests of the Company and its stockholders.

 

The Company has not established a new date for the Annual Meeting at this time. The Company intends to announce the rescheduled date, time, and any related information concerning the Annual Meeting in a subsequent filing with the Securities and Exchange Commission (the “SEC”) and through other appropriate communications.

 

Additional Information and Where to Find It

 

The Company previously filed a Definitive Proxy Statement on Schedule 14A with the SEC relating to the Annual Meeting. Stockholders are encouraged to read the Company’s proxy materials and any supplements thereto because they contain important information. Copies of these documents are available free of charge at www.sec.gov and on the Company’s website.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the rescheduling of the Annual Meeting and related matters. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The Company undertakes no obligation to update any forward-looking statements except as required by law.

 

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 11, 2026

 

  OSR HOLDINGS, INC.
       
  By: /s/ Kuk Hyoun Hwang
    Name:  Kuk Hyoun Hwang
    Title: Chief Executive Officer

 

2

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Osr Health Inc (OSRH)

Reference

Frequently asked questions

When did Osr Health Inc file this 8-K?
Osr Health Inc (OSRH) filed this Current Report (Form 8-K) with the SEC on June 11, 2026. The accession number assigned by EDGAR is 0001213900-26-067732.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
OSR Holdings postpones its 2026 Annual Meeting; a new date has not yet been set. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Osr Health Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Osr Health Inc has filed under CIK 1840425, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer